[PRoFESS study presented. Change in secondary prevention].
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D000068342:Aspirin, Dipyridamole Drug Combination; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D000077144:Clopidogrel; D018849:Controlled Clinical Trials as Topic; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D002546:Ischemic Attack, Transient / Q000517:prevention & control; D015337:Multicenter Studies as Topic; D010919:Placebos; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D012306:Risk; D020521:Stroke / Q000517:prevention & control*; D000077333:Telmisartan; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D000068342:Aspirin, Dipyridamole Drug Combination; D001562:Benzimidazoles; D001565:Benzoates; D004338:Drug Combinations; D010919:Placebos; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin; D000077333:Telmisartan